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Comparison between siblings and twins supports a role for mod-
ifier genes in ADPKD.
Background. Autosomal-dominant polycystic kidney disease
(ADPKD) is characterized by intrafamilial variability in renal
disease progression, which could result from a combination of
environmental and genetic factors. Although a role for modifier
genes has been evidenced in mouse models, direct evidence in
ADPKD patients is lacking. The analysis of variability in af-
fected siblings and monozygotic (MZ) twins would help evalu-
ate the relative contribution of environment and genetic factors
on renal disease progression in ADPKD.
Methods. The difference in the age at end-stage renal disease
(ESRD) and the intraclass correlation coefficient (ICC) were
quantified in a large series of ADPKD siblings from western
Europe and compared with the values obtained in a series of
MZ ADPKD twins from the same geographic area.
Results. Fifty-six sibships (including 129 patients) and nine
pairs of MZ twins were included. The difference in the age at
ESRD was significantly higher in siblings (6.9 ± 6.0 years, range
2 months to 23 years) than in MZ twins (2.1 ± 1.9 years, range 1
month to 6 years; P = 0.02). Furthermore, the intraclass corre-
lation coefficient was significantly lower in siblings than in MZ
twins (0.49 vs. 0.92, respectively; P = 0.003). The intrafamilial
difference in the age at ESRD was not influenced by gender.
Conclusion. These data substantiate the existence of a large
intrafamilial variability in renal disease progression in ADPKD
siblings. The fact that the variability in siblings is in a significant
excess of that found in MZ twins strongly suggests that modifier
genes account for a significant part of this variability.
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common inherited renal disease,
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accounting for 5% to 10% of patients requiring renal
replacement therapy. ADPKD is characterized by the
development of multiple cysts in both kidneys, leading
to end-stage renal disease (ESRD) in about half of the
patients by the age of 50 years [1]. The disease is due
to mutations in two genes, PKD1, responsible for about
85% of cases, and PKD2, which accounts for the vast
majority of the remaining cases [2]. The proteins encoded
by PKD1 and PKD2 (polycystin-1 and polycystin-2,
respectively) probably interact in the primary cilia of
renal epithelial cells to participate in complex signal
transduction pathways involved in mechanosensory
function and renal tubular cell maturation and/or
proliferation [2].
One of the most striking aspects of ADPKD is the ex-
istence of an important variability in renal disease pro-
gression [3]. Interfamilial variability in the age at ESRD
is well established. It has been attributed to the distinct
effects of mutations in PKD1 and PKD2 [4], the position
of the mutation itself [5], and also environmental factors
[3]. Intrafamilial variability in the age at ESRD has been
observed in large ADPKD families [6], dizygotic (DZ)
twins [7], affected parent-offspring pairs [8] and, most re-
cently, families characterized for PKD1 [5] and PKD2 [9]
mutations. Such variability could result from a combina-
tion of environmental and genetic factors, influencing all
the steps leading to the disease [3]. Data obtained both
in patients and mouse models suggest that cyst formation
in ADPKD epithelia is triggered by a second hit (i.e.,
the occurrence of a somatic mutation in the allele unaf-
fected by germline mutation) [10]. Micro-environmental
or genetic factors determining the rate of second hit could
thus modulate cystogenesis and, thereby, renal disease
progression. Alternatively, modifier genes in ADPKD
patients could affect the polycystins-mediated sig-
nal transduction pathways, play a role in cyst fluid
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accumulation, or influence other mechanisms involved
in the progression of the disease [3, 11].
Although a role for modifier genes has been evidenced
in mouse models of ADPKD [12], studies in ADPKD
patients are required to evaluate the importance of ge-
netic versus environmental factors in renal disease pro-
gression. The analysis of intrafamilial variability in renal
disease progression in ADPKD in multigenerational fam-
ilies [5, 6] and parent-offspring pairs [8] is not optimal to
identify the possible contribution of modifier genes be-
cause differences in environment and way of life, and
also distinctive medical care, may influence renal disease
progression [13, 14]. The quantification of the variability
in the age at ESRD in affected ADPKD siblings, who
theoretically share a more similar environment and med-
ical care than patients from multiple generations, and its
comparison with the variability observed in genetically
identical monozygotic (MZ) ADPKD twins, would be a
strong element to evaluate the contribution of modifier
genes influencing renal disease progression.
In order to uncover the contribution of modifier genes,
we compared the variability in the age at ESRD in a
large series of ADPKD sibships with that observed in
MZ ADPKD twins.
METHODS
ADPKD siblings
During the three-year recruitment period (September
1998–September 2001), we looked for patients with
ADPKD at ESRD (dialysis or transplantation) in four
academic institutions: Saint-Luc Academic Hospital,
Brussels (Belgium), U.Z. Gasthuisberg, Leuven
(Belgium), Necker Hospital, Paris (France), and
Complexo Hospitalario Universitario, Santiago (Spain).
If these patients (index cases) had at least one affected
sibling also at ESRD at that time, they were included
in the analysis. Within sibships, all affected siblings at
ESRD at the time of recruitment were taken into account
(i.e., two or more within each family). Thus, all siblings
included had reached ESRD before September 2001, and
many of them before September 1998. The diagnosis of
ADPKD was established on the basis of well-established
criteria, including bilateral enlarged cystic kidneys and
a family history suggestive of autosomal-dominant
inheritance [1]. The age at ESRD was defined as the age
at starting renal replacement therapy. Linkage analysis
for PKD1 and PKD2 was performed in informative
families as described previously [15], and known PKD2
families (N = 2) were excluded from the analysis.
The study was approved by the ethics committee of
each center; informed consent was obtained from all
patients.
Table 1. Intrafamilial variability in renal disease progression in
ADPKD: Comparison between families of siblings and monozygotic
twins
Families of MZ twins
siblings pairs P value
N 56 9
(N of ADPKD patients) (129) (18)
Mean difference of age at 5.2 ± 6.5 0.0
birth years
Mean difference in age at 6.9 ± 6.0a 2.1 ± 1.9 0.02b
ESRD years
Intraclass correlation coefficientc 0.49d 0.92d 0.003e
Abbreviations are: ADPKD, autosomal-dominant polycystic kidney disease;
MZ, monozygotic; ESRD, end-stage renal disease.
aAfter adjustment for difference of age for date of birth.
bMann-Whitney U test.
cOne-way ANOVA.
dThe ICC was significant (P < 0.0001) within each group.
eF test.
ADPKD monozygotic twins
MZ twins affected with ADPKD were identified in the
series of 32 twins recruited through a European Con-
certed Action [16]. Determination of zygosity using ques-
tionnaires, comparison of blood groups, HLA antigens
and, when necessary, hypervariable DNA markers, al-
lowed the identification of 20 pairs of MZ twins. Among
these 20 MZ pairs, nine pairs had reached ESRD and
were included in the study. The analysis of variability was
thus performed in a series of nine MZ ADPKD twin pairs
at ESRD.
Statistical analyses
The Gaussian distribution of age at ESRD was verified
by the Shapiro-Wilk’s W test. Similarity for renal dis-
ease progression in ADPKD siblings and MZ twins was
assessed by the mean difference in the age at ESRD (ad-
justed for the difference of date of birth for siblings) and
the intraclass coefficient (ICC) [17]. The Mann-Whitney
U test was used to compare the intrasibship differences
in the age at ESRD. The intraclass correlation coefficient
(ICC) is a classic mean of evaluating the heritability of
quantitative traits in twins or siblings. It is a measure of
the similarity of observations (here, the age at ESRD)
within sibships compared to that between sibships. As a
ratio, it might vary from 0 to 1. The higher the similarity
within sibships, the higher the ICC. The ICC was com-
puted by a one-way analysis of variance (ANOVA) in
which observations were grouped by family to provide
estimates of resemblance based on the variability within
and between families [17]. The degrees of similarity in
MZ twin pairs and sibships were compared using the F
test for comparison of ICCs [17]. The values are reported
as mean ± SD (Tables 1 and 2).
RESULTS
Fifty-six consecutive families including two (N = 43),
three (N = 10), four (N = 2), or five (N = 1) siblings at
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Table 2. Variability in the age at ESRD within same-gender and
opposite-gender pairs of siblings affected with ADPKD
Same Opposite
gender gender P value
N of pairs 60a 35a
Mean difference of age at 5.5 ± 4.0 4.6 ± 3.1 0.22
birth years
Mean age at ESRD years 51.2 ± 9.1 51.3 ± 7.9 0.89
Mean difference of age at 7.3 ± 6b 6.1 ± 6b 0.35
ESRD years
Intraclass correlation coefficientc 0.56 0.44 0.26
aAll the possible pairs within the 56 families with siblings were included in the
analysis.
bAfter adjustment for difference of age for date of birth.
cThe ICC was significant for the same gender (P = 0.0001) and opposite
gender (P = 0.002) groups.
ESRD (total: 129 patients), and nine pairs of MZ twins
at ESRD were recruited (Table 1). The year of birth was
similar in siblings and twins (median year: 1940 in both
groups). The distribution of the age at ESRD was not sig-
nificantly different from a Gaussian distribution in both
groups. The mean age at ESRD of the 56 index patients
was 51.2 ± 8.5 years (range 33–69 years), similar to that
reported in PKD1-linked patients in general [4, 5] and
those linked to PKD1 in this study (51.0 ± 7.7 years, N =
23). The mean age at ESRD was 46.8 ± 7.4 years in the
MZ twins (range 36–59 years). The age at ESRD was not
influenced by center.
The differences in the age at ESRD within the 56 fam-
ilies of siblings were highly variable, ranging from two
months to 23 years. The intrafamilial difference in the age
at ESRD averaged 6.9 ± 6.0 years in the 56 families and
6.1 ± 4.4 in the 23 PKD1-linked sibships. The variance
within siblings estimated by the ICC was 0.49 (95% CI
0.74–0.22; P < 0.0001). The mean difference in the age
at ESRD among the nine pairs of MZ twins was 2.1 ±
1.9 years (range 1 month to 6 years), whereas the ICC
within this group was 0.92 (95% CI 0.98–0.92; P < 0.0001).
The difference in the age at ESRD in siblings (6.9 ±
6.0 years) was significantly higher than that observed in
MZ twins (2.1 ± 1.9 years) (Mann-Whitney U test, P =
0.02). Furthermore, the variability within sibships, com-
puted with the ANOVA method, was also significantly
higher in siblings (N = 56, within variance: 37.99) than
in MZ twins (N = 9, within variance: 4.98) (F = 8.67,
P = 0.003), thus reflecting the increased ICC in the latter
(Table 1).
There was no significant effect of gender on the age at
ESRD either in siblings (males 50.6 ± 8.8 years, N = 71
vs. females 52.0 ± 8.1 years, N = 58; P = 0.34) or MZ
twins (males 45.0 ± 7.8 years, N = 12 vs. females 50.5 ±
5.4 years, N = 6; P = 0.14). These data were confirmed
by a systematic analysis of the variability in the age at
ESRD within same- and opposite-gender pairs, taking
into account all the possible pairs within the 56 ADPKD
families with siblings (Table 2). Considering that renal
failure may progress more slowly in females than males
with ADPKD, a selection bias in gender recruitment was
not excluded. However, the elimination of the non-ESRD
patients was not reflected by a preferential loss of females
or a significant change in the gender ratio in our series
(data not shown).
DISCUSSION
This study is the first detailed assessment of intrafamil-
ial variability in renal survival comparing siblings and MZ
twins with ADPKD. Intrafamilial variability in renal dis-
ease progression is commonly observed in ADPKD, as re-
cently shown in multigeneration PKD1 [5] and PKD2 [9]
families. In particular, coexistence of young patients with
ESRD and elderly patients with moderate renal failure
was noted within such families [5, 9]. However, the poten-
tial impact of enhanced awareness about risk factors for
renal progression (e.g., smoking, hypertension) and more
efficient antihypertensive treatment could hamper the
analysis of renal progression in multigenerational fam-
ilies [3, 13, 14]. The present study, which is restricted to
siblings, who arguably share a similar environment and
way of life at least until adulthood, and benefit from sim-
ilar medical care [3, 14], thus confirms and extends the
findings obtained in multigenerational families [4, 5, 6, 8,
9].
Most importantly, our study demonstrates a signifi-
cant excess of variability in renal disease progression in
ADPKD siblings versus MZ twins. The difference be-
tween the two groups is reflected both by the age at ESRD
and by the intrasibship variability, as shown by the ICC
(Table 1). Consistent with findings in PKD1 and PKD2
families [5, 9], the discordant variability among siblings
and MZ twins represents a strong argument for modifier
genes influencing renal disease progression in ADPKD.
The difference in the age at ESRD within sibships theo-
retically results from the interplay between genetic and
environmental factors. By contrast, in genetically identi-
cal MZ twins, the difference can only be explained by
environmental factors and/or the rate of somatic mu-
tations in PKD1 or PKD2, if the latter is a stochastic
event that plays an early role in cystogenesis [10]. It must
be said, however, that this reasoning could have limita-
tions, since MZ twins are probably not genetically iden-
tical in all tissues and may have experienced differences
in placental vascular supply and/or cell number alloca-
tion during very early post-zygotic events [18]. Neverthe-
less, since ADPKD siblings and MZ twins studied here
share a roughly similar environment (date of birth, ge-
ographic origin), the excess of variability found within
siblings should be mainly explained by genetic factors
[19].
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It is increasingly recognized that the phenotype of
Mendelian disorders is influenced by modifier genes (i.e.,
inherited genetic variations distinct from the disease lo-
cus) [20]. Such modifier genes have been evidenced in
murine models of polycystic kidney disease [12]. Further-
more, recent studies have demonstrated a greater-than-
additive cystic phenotype in trans-heterozygous Pkd1+/−:
Pkd2+/− mice versus singly heterozygous Pkd1+/− or
Pkd2+/− mice that is best explained by a modifier ef-
fect exerted by the polycystins genes themselves [21]. A
few studies have investigated candidate genes in ADPKD
patients, including the polymorphisms of the angiotensin-
converting enzyme (ACE) and endothelial nitric oxide
synthase (ENOS or NOS3) genes, or mutations in the CF
gene that encodes the cAMP-regulated CFTR chloride
channel [5, 15, 22–26]. These studies yielded divergent
results, which can be explained by small sample size, pop-
ulation admixture, and lack of consideration of genetic
and environmental factors [27].
Two aspects of this study should be further commented.
The first is the relative rarity of twins recruited. It is
generally assumed that about 1 in 40 babies born in Eu-
rope will be a twin [28]. Considering the prevalence of
ADPKD (1:400 to 1:1000), one should expect a preva-
lence of twins with ADPKD ranging approximately from
25 to 60 per million living births. Despite a multicentric
effort involving academic centers centralizing the recruit-
ment of ADPKD patients, only 32 pairs could be recruited
and analyzed. Furthermore, although DZ twins should
be twice as numerous as MZ twins in Caucasians, only
12 DZ twins versus 20 MZ twins were recruited. One ex-
planation is that twins were not recruited just because
they were not identified as such by the referring physi-
cians. This potential bias is illustrated by the small size of
many twin series, and by the fact that discordant DZ twins
may classically escape inclusion [16, 19]. The point must
be noted since DZ twins would be even more adequate
control than siblings to evaluate the influence of envi-
ronment [19]. Alternatively, the low twinning rate could
reflect a discrete fertility problem in the ADPKD popu-
lation. In contrast with the rate of MZ twinning, which is
stable in humans, DZ twinning occurs at different rates
that probably reflect geographic, seasonal, and familial
variations in polyovulation. The spontaneous DZ twin-
ning rate is an index of the combination of male plus
female fertility [28, 29], and a lagged correlation between
decreased DZ twinning rates and sperm counts has been
suggested [30]. There is no evidence suggesting fertility
problems in females with ADPKD [1]. In contrast, infer-
tility associated with necrospermia [31] or axonemal 9+0
defects in the sperm flagella [32] has been documented
in ADPKD patients. A role of polycystins in male fer-
tility is further suggested by studies in model organisms,
which showed that the Drosophila homolog of polycystin-
2 is required for sperm movement and male fertility [33],
whereas the association of homologs of polycystin-2 and
polycystin-1 could mediate the sperm acrosomal reaction
in the sea urchin [34]. Another hypothesis arises from
the cardiac and vascular abnormalities observed in sev-
eral mouse models of ADPKD with targeted mutations
in Pkd1 and Pkd2 [12]. Abnormalities in placentation or
arteriovenous malformations have a critical influence on
fetal development and neonatal outcome in multiple ges-
tations [35] and, by extension, may also participate in the
low prevalence of twinning in ADPKD.
The second aspect is the lack of influence of gender on
renal disease progression, as shown by a similar differ-
ence in the age at ESRD in same and opposite gender
pairs (Table 2). Male gender has been associated with an
earlier age at ESRD in the whole ADPKD population
[36, 37]. However, recent studies suggest that this gender
effect, which has not been found in PKD1 families [4, 5,
15], could be restricted to PKD2 families [9].
CONCLUSION
We have characterized the intrafamilial variability in
renal disease progression in a large series of ADPKD
siblings and MZ twins. The sibling analysis and the excess
variability compared to MZ twins support the existence
of modifier genes influencing renal survival in ADPKD.
These data provide a strong rationale for the design of
a multicentric sib-pair study looking for modifier loci in
human ADPKD.
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